Keyphrases
Recombinant
100%
Fusion Protein
100%
Ulcerative Colitis
100%
Oral Administration
100%
Anti-tumor Necrosis Factor (anti-TNF)
100%
Orally Administered
100%
Phase 2a Clinical Trial
100%
Clinical Remission
66%
Clinical Response
66%
Immune Regulation
66%
Inflammatory Immune Response
66%
Calprotectin
66%
Geboes Score
66%
Mild-to-moderate Ulcerative Colitis
66%
Lymphocytes
33%
Non-associated
33%
Interleukin-6
33%
Serum Levels
33%
Clinical Efficacy
33%
Plant Cells
33%
Immune Parameters
33%
Clinical Effect
33%
High-sensitivity C-reactive Protein (hs-CRP)
33%
Once-daily
33%
Cell Cytokines
33%
Fluorescence-activated Cell Sorting
33%
Interferon-γ
33%
Mayo Score
33%
Cytokine Levels
33%
Forkhead Box P3 (FOXP3)
33%
CD4+CD25+
33%
Open-label Trial
33%
Non-absorbable
33%
Immune Suppression
33%
Medicine and Dentistry
Clinical Trial
100%
Fusion Protein
100%
Tumor Necrosis Factor
100%
Ulcerative Colitis
100%
Oral Drug Administration
100%
Anti-Inflammatory Drug
66%
Immunomodulation
66%
Calgranulin
66%
Cytokine
33%
Gamma Interferon
33%
Immunosuppressive Treatment
33%
Fluorescence Activated Cell Sorting
33%
Patient with Ulcerative Colitis
33%
Recombinant
33%
Open-Label Trial
33%
Lymphocyte
33%
Interleukin 6
33%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Tumor Necrosis Factor
100%
Ulcerative Colitis
100%
Fusion Protein
100%
Anti-Inflammatory Drug
50%
Remission
50%
Calgranulin
50%
Fluorescence Activated Cell Sorting
25%
Recombinant
25%
Cytokine
25%
Open-Label Trial
25%
Gamma Interferon
25%
Interleukin 6
25%